InsidersTradesSigma
Sol-Gel Technologies Ltd. Stock: price and insider trades · United States · SEC (Form 4)
Track the Sol-Gel Technologies Ltd. stock price and the full management transaction log of the company, a listed equity based in United States. Shares trade on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Sol-Gel Technologies Ltd. has logged 18 insider filings. Market capitalisation: €249.6m. The latest transaction was disclosed on 10 July 2026 (Acquisition). Among the most active insiders: Opaleye Management Inc.. All data is free.
18
Insider Decl.
0
Thresholds
€3m
18 ops.
Buy Volume
·
0 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Sol-Gel Technologies Ltd. Strong Buy (bullish), based on 3 analysts. Average price target: US$193.00.
21Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 23,415 of 26,220 companies
22.7
score / 100
Value30
Quality15
FCF yld0.2%
Earn yld-5.2%
EV/EBITDA·
ROE-2.9%
Gross mgn·
Net mgn-32%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 10 July 2026
Declarations18 total
300 shares@ US$73.690.0089% mcap0.6% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-032859:0
Ideal exit: 4 Apr 2027 (T+270)
229 shares@ US$73.950.0068% mcap0.5% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-032859:1
Ideal exit: 6 Apr 2027 (T+270)
1,500 shares@ US$67.98330.037% mcap50.0% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-26-023056:0
Ideal exit: 6 Feb 2027 (T+270)
34,665 shares@ US$72.0096.1% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-26-012354:0
Ideal exit: 19 Dec 2026 (T+270)
291 shares@ US$63.000.5% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-26-007330:0
Ideal exit: 10 Nov 2026 (T+270)
100 shares@ US$58.000.1% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-26-007306:0
Ideal exit: 30 Oct 2026 (T+270)
100 shares@ US$58.000.1% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-26-005094:0
Ideal exit: 30 Oct 2026 (T+270)
100 shares@ US$57.050.1% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-26-004234:0
Ideal exit: 24 Oct 2026 (T+270)
2,173 shares@ US$56.56813.2% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-26-003468:0
Ideal exit: 19 Oct 2026 (T+270)
2,394 shares@ US$41.91642.6% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-26-000588:0
Ideal exit: 29 Sept 2026 (T+270)
8,638 shares@ US$41.85399.4% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-25-029866:0
Ideal exit: 25 Sept 2026 (T+270)
1,019 shares@ US$41.15371.3% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-25-029359:0
Ideal exit: 18 Sept 2026 (T+270)
2,735 shares@ US$40.37013.5% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-25-028550:0
Ideal exit: 13 Sept 2026 (T+270)
87 shares@ US$40.000.1% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-25-027959:0
Ideal exit: 8 Sept 2026 (T+270)
444 shares@ US$39.49730.6% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-25-026848:0
Ideal exit: 1 Sept 2026 (T+270)
4,340 shares@ US$37.36565.4% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-25-026021:0
Ideal exit: 28 Aug 2026 (T+270)
6 shares@ US$35.500.0% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-25-025138:0
Ideal exit: 21 Aug 2026 (T+270)
5,784 shares@ US$35.83057.4% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-25-024624:0
Ideal exit: 17 Aug 2026 (T+270)
18 of 18 declarations
About Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd. is a U.S.-listed specialty biopharmaceutical company traded on the NASDAQ in the United States (United States), with a focused footprint in dermatology. The company was founded on October 28, 1997, and is headquartered in Ness Ziona, Israel, at Weizmann Science Park. Its core strategy is centered on developing and commercializing topical therapies for severe, rare, and high-unmet-need skin diseases, supported by a proprietary microencapsulation-based formulation platform designed to improve local delivery and tolerability of dermatologic actives. ([ir.sol-gel.com](https://ir.sol-gel.com/resources/investor-faqs?utm_source=openai)) Sol-Gel’s commercial history is anchored by two FDA-approved products: TWYNEO®, for acne vulgaris in adults and pediatric patients nine years of age and older, and EPSOLAY®, for inflammatory lesions of rosacea in adults. These approvals demonstrate the company’s ability to progress dermatology assets through clinical development and regulatory review. More recently, Sol-Gel has shifted increasing attention toward its proprietary pipeline, led by SGT-610, a topical patidegib gel currently in Phase 3 development for the prevention of new basal cell carcinoma lesions in patients with Gorlin syndrome. The pipeline also includes SGT-210, a topical erlotinib candidate being studied in Darier disease and other rare keratinization disorders. ([ir.sol-gel.com](https://ir.sol-gel.com/node/8896?utm_source=openai)) From a competitive standpoint, Sol-Gel remains a niche player relative to large global dermatology and specialty-pharma groups, but it has carved out a differentiated profile through focused topical formulation expertise, demonstrated regulatory execution, and a partnership-driven commercialization model outside the United States. The company has signed multiple ex-U.S. licensing agreements for TWYNEO and EPSOLAY, including arrangements in Europe, South Africa, Australia, and New Zealand, which broaden geographic reach while reducing the need for a large internal sales infrastructure. ([ir.sol-gel.com](https://ir.sol-gel.com/news-releases/news-release-details/sol-gel-announces-signing-six-exclusive-license-agreements?utm_source=openai)) A key recent development was the April 2025 sale of the U.S. rights to EPSOLAY and TWYNEO to Mayne Pharma, following the mutual termination of Sol-Gel’s exclusive U.S. license agreement with Galderma. That transaction materially reshaped the company’s U.S. commercial exposure and made the clinical pipeline, especially SGT-610, even more central to the investment case. In March 2026, Sol-Gel also completed a new underwritten offering, underscoring that liquidity management and capital access remain important priorities as the company continues to fund clinical development and prepare for potential future commercialization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1684693/000117891325002946/exhibit_99-1.htm?utm_source=openai))
